Molecular characterization of Clostridioides difficile isolated from older adults during prospective population-based active surveillance at nine hospitals in Tokyo, Japan, 2018–2020
Zhenghui Li(Pfizer (United States)), Kazuhiro Tateda(Toho University), C Hal Jones(Pfizer (United States)), Jennifer C. Moïsi(Pfizer (France)), Lubomira Andrew(Pfizer (United States)), Ashlesh K. Murthy(Pfizer (United States)), Warren V. Kalina(Pfizer (United States)), Kwok Lee(Pfizer (United States)), Richard V. Goering(Creighton University), Michael W. Pride(Pfizer (United States)), Urvi Rajyaguru(Pfizer (United States)), Shuhei Ito(Pfizer (Japan)), Elisa Gonzalez(Pfizer (United States)), Frederick J. Angulo(Pfizer (United States)), Deepika Athinarayanan(Pfizer (United States)), Paul Liberator(Pfizer (United States))
Cited by 1
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Foodborne Illness Acquired in the United States—Major Pathogens
|Emerging infectious diseases|2010|7.6k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k